On April 16, 2026 SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, reported that the Mount Sinai Health System, one of the leading academic health systems in the United States, will adopt the AI-powered SOPHiA DDM Platform to advance cancer research and enhance genomic testing capabilities.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mount Sinai, a National Cancer Institute-designated Comprehensive Cancer Center in New York City, supports care for more than 4,000 oncology patients annually. Mount Sinai’s Molecular Pathology team will leverage SOPHiA DDM to strengthen next-generation sequencing (NGS) capabilities for blood cancers and solid tumors. The Platform is designed to enable detection and interpretation of a wide range of complex genomic variants while improving operational efficiency by consolidating critical steps in the analysis pipeline and reducing manual interpretation time.
By combining Mount Sinai’s clinical excellence with SOPHiA DDM’s advanced AI-powered analytics, the hospital will be equipped to interpret complex genomic datasets at scale and optimize laboratory resources, enabling teams to focus on direct patient care.
Jane Houldsworth, Ph.D., Director of Molecular Oncology Pathology of the Mount Sinai Health System, said: "The collaboration between Mount Sinai and SOPHiA GENETICS reinforces our commitment to scientific innovation by integrating powerful digital tools into our workflows to support high-quality, data-driven cancer care. Leveraging SOPHiA DDM has enabled us to reduce hands-on analysis time and improve our testing turnaround times, enabling our clinicians to provide better patient care."
John Carey, Managing Director, North America, SOPHiA GENETICS, said: "Mount Sinai is widely regarded as one of the world’s leading centers for cancer research and was recently ranked No. 1 globally among health care institutions in the Nature AI Index, underscoring its leadership in artificial intelligence and data-driven innovation. We are honored to support their teams with an AI-native platform and global network designed to deliver faster results, greater operational efficiency, and deeper genomic understanding to help shape the future of precision oncology."
By utilizing the SOPHiA DDM for Blood Cancers and SOPHiA DDM for Solid Tumors applications, Mount Sinai joins a growing network of more than 990 global institutions using SOPHiA GENETICS’ decentralized platform to accelerate precision medicine. This collaboration underscores SOPHiA GENETICS’ mission to democratize data-driven medicine, delivering scalable, cloud-native solutions that empower healthcare institutions to expand access to advanced genomic testing and improve patient outcomes worldwide.
The collaboration was announced from the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego. Learn more by connecting with SOPHiA GENETICS at AACR (Free AACR Whitepaper) booth #4248 from April 17 – 22, 2026.
(Press release, Mount Sinai Hospital, APR 16, 2026, View Source [SID1234664442])